A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma

This study is testing anlotinib (a targeted anti-cancer drug) with or without a PD-1 immune checkpoint inhibitor in patients with high-grade chondrosarcoma — a rare bone cancer — that cannot be surgically removed and has not been treated with these drug types before. **You may be eligible if...** - You are 18 or older with confirmed high-grade or dedifferentiated chondrosarcoma that is unresectable or has spread - You are in good health (ECOG 0–2) with adequate organ function - You have at least one measurable tumor - You may have had prior surgery, radiation, or chemotherapy **You may NOT be eligible if...** - You have previously received anti-PD-1/PD-L1 immunotherapy - You have previously received anlotinib or similar anti-angiogenic drugs - You have received other anti-cancer therapy within 4 weeks of enrollment - You have uncontrolled high blood pressure, a recent heart attack, or stroke within 6 months - You have significant bleeding risk, active infection, or active liver disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.